"Thanks to new Multiplicom test kits physicians are able to identify all the genetic mutations of a condition at once, and use this information to initiate the right - personalized - treatment.”
Genomeweb: German Genomic Service Provider Details Implementation of Multiplicom's NIPT
BOCHUM (Germany) – Noninvasive prenatal testing has traditionally been mostly performed by centralized testing laboratories, but several providers – including Multiplicom of Belgium and UK-based Premaitha Health – have launched CE-marked NIPT tests that allow laboratories to implement the assay locally.
Multiplicom, which was recently acquired by Agilent Technologies, launched the Clarigo test in 2015. The test assesses fetal risk of trisomy 21, 18, and 13 and determines fetal sex as an option. It uses a targeted next-gen sequencing approach that relies on the company's proprietary multiplex PCR technology, called MASTR (multiplex amplification-specific targets for resequencing). Multiplicom validated the test with three laboratories on more than 1,900 samples, initially using Illumina's MiSeq and HiSeq.
Click here to read the full article on Genomeweb.
Click here to see more information on our Clarigo NIPT solution.